Compare ASE Technology Holding Co Ltd (ASX) vs Hims and Hers Health Inc (HIMS) Price & Performance

ASE Technology Holding (ASX) trades at $37.59, up 0.53% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, exceeding expectations, and announced a $10.5 billion capital expenditure increase for AI-driven semiconductor demand (Reuters, 2026-07-30). Financials show revenue growth to $645.39 billion in 2025 and a net income margin of 8.46%, though valuation ratios like P/E of 47.78 appear elevated.

Outlook is positive due to AI capacity expansion and robust institutional interest, with 80% analyst buy ratings. Risks include high valuation sensitivity and execution challenges from increased capital spending. The stock's momentum is supported by earnings growth, but investors should monitor margin sustainability amid competitive pressures.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.